Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform

被引：847

作者：

Zhang, Liangfang ^{[2
,3
]}

Chan, Juliana M. ^{[4
]}

Gu, Frank X. ^{[2
,3
]}

Rhee, June-Wha ^{[1
]}

Wang, Andrew Z. ^{[1
,2
,3
]}

Radovic-Moreno, Aleksandar F. ^{[2
,3
]}

Alexis, Frank ^{[1
,2
,3
]}

Langer, Robert ^{[2
,3
]}

Farokhzad, Omid C. ^{[1
]}

机构：

[1] Harvard Univ, Brigham Womens Hosp, Sch Med, Lab Nanomed & Biomat,Dept Anesthesiol, Boston, MA 02115 USA

[2] MIT, Dept Chem Engn, Cambridge, MA 02139 USA

[3] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA

[4] MIT, Dept Biol, Cambridge, MA 02139 USA

来源：

ACS NANO | 2008年 / 2卷 / 08期

基金：

美国国家卫生研究院;

关键词：

polymeric nanoparticle; liposome; self-assembly; nanoprecipitation; drug delivery;

D O I：

10.1021/nn800275r

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

We report the engineering of a novel lipid-polymer hybrid nanoparticle (NP) as a robust drug delivery platform, with high drug encapsulation yield, tunable and sustained drug release profile, excellent serum stability, and potential for differential targeting of cells or tissues. The NP comprises three distinct functional components: (i) a hydrophobic polymeric core where poorly water-soluble drugs can be encapsulated; (ii) a hydrophilic polymeric shell with antibiofouling properties to enhance NP stability and systemic circulation half-life; and (iii) a lipid monolayer at the interface of the core and the shell that acts as a molecular fence to promote drug retention inside the polymeric core, thereby enhancing drug encapsulation efficiency, increasing drug loading yield, and controlling drug release. The NP is prepared by self-assembly through a single-step nanoprecipitation method in a reproducible and predictable manner, making it potentially suitable for scale-up.

引用

页码：1696 / 1702

页数：7

共 20 条

[1] Proofs of the structure of lipid coated nanoparticles (SMBV™) used as drug carriers [J].

De Miguel, I ;

Imbertie, L ;

Rieumajou, V ;

Major, M ;

Kravtzoff, R ;

Betbeder, D .

PHARMACEUTICAL RESEARCH, 2000, 17 (07) :817-824

[2] Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo [J].

Farokhzad, OC ;

Cheng, JJ ;

Teply, BA ;

Sherifi, I ;

Jon, S ;

Kantoff, PW ;

Richie, JP ;

Langer, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (16) :6315-6320

[3] Nanomedicine: Developing smarter therapeutic and diagnostic modalities [J].

Farokhzad, Omid C. ;

Langer, Robert .

ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (14) :1456-1459

[4] Cancer nanotechnology: Opportunities and challenges [J].

Ferrari, M .

NATURE REVIEWS CANCER, 2005, 5 (03) :161-171

[5] Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers [J].

Gu, Frank ;

Zhang, Liangfang ;

Teply, Benjamin A. ;

Mann, Nina ;

Wang, Andrew ;

Radovic-Moreno, Aleksandar F. ;

Langer, Robert ;

Farokhzad, Omid C. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (07) :2586-2591

[6] Nanoparticle-mediated cellular response is size-dependent [J].

Jiang, Wen ;

Kim, Betty Y. S. ;

Rutka, James T. ;

Chan, Warren C. W. .

NATURE NANOTECHNOLOGY, 2008, 3 (03) :145-150

[7] Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies [J].

Kim, TY ;

Kim, DW ;

Chung, JY ;

Shin, SG ;

Kim, SC ;

Heo, DS ;

Kim, NK ;

Bang, YJ .

CLINICAL CANCER RESEARCH, 2004, 10 (11) :3708-3716

[8]

Langer R, 1998, NATURE, V392, P5

[9]

Lupold SE, 2002, CANCER RES, V62, P4029

[10] Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties [J].

Moghimi, SM ;

Szebeni, J .

PROGRESS IN LIPID RESEARCH, 2003, 42 (06) :463-478

← 1 2 →